Brepocitinib for skin sarcoidosis
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests an oral drug called brepocitinib to see if it can help people with skin sarcoidosis and reduce skin symptoms. It aims to find a better treatment option for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of skin sarcoidosis with a skin biopsy.
- Your skin condition must be active, with a certain level of severity.
- You must weigh between 40 kg (about 88 lbs) and less than 130 kg (about 287 lbs), and your body mass index (BMI) must be 45 or lower.
- You must not have a history of cancer (except for certain fully removed skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether sirolimus, a medicine that calms the immune system, can improve skin sarcoidosis on the face. It may help people whose skin symptoms are moderate to severe and haven't improved with other treatments.
This trial tests a pill called baricitinib to see if it can reduce inflammation in the heart caused by sarcoidosis. The goal is to help control the disease and improve heart function.
This trial tests an experimental drug to see if it can help people with pulmonary sarcoidosis, which affects the lungs. The drug may work by reducing inflammation, and this study will check its safety and effectiveness.
This trial tests a steroid medication called compound betamethasone for people with newly diagnosed pulmonary sarcoidosis (stage I or II). It may help reduce inflammation and improve symptoms compared to standard prednisone treatment.
This trial studies a treatment approach for people with active cardiac sarcoidosis, confirmed by specific heart rhythm/heart function problems and a PET scan. It may help by targeting the active inflammation driving heart conduction problems, rhythm events, or weak heart pumping.
This trial tests an experimental drug called XTMAB-16 for people with sarcoidosis in the lungs, which may also affect other parts of the body. The goal is to see if it helps improve breathing and reduce symptoms.
Hear when a new Cutaneous Sarcoidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.